N-Salicyloyltryptamine

Name: N-Salicyloyltryptamine
Brand: MedChemExpress
SKU: HY-147377
Rating: 4.5 (1 reviews)

Cat. No.: HY-147377 Purity: 96.37%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

N-Salicyloyltryptamine acts on voltage-dependent Na⁺, Ca²⁺, and K⁺ ion channels inhibitor. N-Salicyloyltryptamine inhibits K⁺ currents with an IC₅₀ value of 34.6 μM (I_to). N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect^-.

For research use only. We do not sell to patients.

N-Salicyloyltryptamine Chemical Structure

CAS No. : 31384-98-2

Size	Price	Stock	Quantity
5 mg	USD 112	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 180	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Calcium Channel Isoform Specific Products:

View All Isoforms

N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

View All ERK Isoform Specific Products:

View All Isoforms

ERK ERK1 ERK2 ERK5 ERK8

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

L-type calcium channel

potassium channel

34.6 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 100 μM Compound: E1	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 31057737]
BV-2	IC₅₀	> 100 μM Compound: 23	Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 32182488]
BV-2	IC₅₀	26.4 μM Compound: 23	Inhibition of LPS-induced NO production in mouse BV-2 cells incubated for 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse BV-2 cells incubated for 24 hrs by Griess reagent based assay	[PMID: 32182488]
BV-2	IC₅₀	26.84 μM Compound: Cpd H	Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 34923430]
C6	IC₅₀	> 100 μM Compound: 23	Cytotoxicity against rat C6 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against rat C6 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 32182488]
C6	IC₅₀	> 40 μM Compound: 23	Inhibition of LPS-induced NO production in rat C6 cells incubated for 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in rat C6 cells incubated for 24 hrs by Griess reagent based assay	[PMID: 32182488]
HeLa	IC₅₀	> 100 μM Compound: E1	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 31057737]
HepG2	IC₅₀	> 100 μM Compound: E1	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 31057737]
HepG2	EC₅₀	0.21 μM Compound: CD6	Induction of ABCA1 transcriptional activity in ABCA1p-LUC human HepG2 cells assessed as luciferase activity after 18 hrs Induction of ABCA1 transcriptional activity in ABCA1p-LUC human HepG2 cells assessed as luciferase activity after 18 hrs	[PMID: 25147608]
HT-22	IC₅₀	101.48 μM Compound: Cpd H	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 34923430]
MCF7	IC₅₀	> 100 μM Compound: E1	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 31057737]
MGC-803	IC₅₀	> 100 μM Compound: E1	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 31057737]

In Vitro

N-Salicyloyltryptamine (1 ng/mL-1 μg/mL; 24 h) presents no cytotoxicity and causes no oxidative stress in RAW 264.7 cells at low concentration, but (50 and 100 μg/mL) inhibits cell viability with an IC₅₀ value of 22.75 μg/mL^[1].
N-Salicyloyltryptamine (1 μg/mL; 24 h) reverses some redox and inflammatory parameters induced by LPS without interfering in cell viability^[1].
N-Salicyloyltryptamine (1 μg/mL; 24 h) inhibits LPS-induced TNF-α and IL-1β release, as well as CD40 and TNF-α protein up-regulation^[1].
N-Salicyloyltryptamine (1 μg/mL; 24 h) inhibits phosphorylation of ERK 1/2 and IκBα and p65 nuclear translocation (NF-kB activation)^[1].
N-Salicyloyltryptamine (17 μM) inhibits K⁺ current by 59.27% (I_to) and 73.18% (I_KD), inhibits L-type Ca²⁺ currents by 54.9%, and shows few inhibition with high concentration (170 μM) on TTX-sensitive Na⁺ current by 22.1% in GH3 cells^[2].
N-Salicyloyltryptamine (0.01 nM-100 μM) produces vasorelaxation through activation of the NO/sGC/cGMP pathway and reduction of calcium influx^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	RAW 264.7 cell
Concentration:	0.001, 0.05, 1, 50, 100 μg/mL
Incubation Time:	24 hours
Result:	Resulted no effect on RAW 264.7 cell viability at 1 μg/mL; however, concentrations of 50 and 100 μg/mL significantly decreased both MTT reduction and SRB incorporation.

RT-PCR^[1]

Cell Line:	RAW 264.7 cell
Concentration:	1 μg/mL
Incubation Time:	24 hours
Result:	Reduced CD40, TNF-α, and RAGE immunocontent. Inhibited ERK1/2 and IκBα phosphorylation and nuclear translocation of p65.

In Vivo

N-Salicyloyltryptamine (100 mg/kg; i.p.; 60 min before stimulation challenge) significantly inhibits pentylenetetrazol (PTZ)-induced seizures and partially eliminates the extensor reflex of maximal electric-induced seizures test^[4].
N-Salicyloyltryptamine (100 mg/kg, 200 mg/kg; i.p.; single dose) shows antinociceptive and nerve excitability effects^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Swiss mice (25-35 g)^[4]
Dosage:	50, 100, 200 mg/kg
Administration:	Intraperitoneal injection; single dose; 60 min before stimulation challenge
Result:	Reduced the incidence of clonic pentylenetetrazol (PTZ) seizures and mortality at 50 mg/kg, and decreased the incidence of tonic hindlimb extension (THE) produced by MES at 100, 200 mg/kg.

Animal Model:	Male Swiss mice (25-35 g)^[5]
Dosage:	100 mg/kg; 200 mg/kg
Administration:	Intraperitoneal injection; single dose
Result:	Reduced the acetic acid-induced licking response of the injected paw.

Molecular Weight

280.32

Formula

C₁₇H₁₆N₂O₂

CAS No.

31384-98-2

Appearance

Solid

Color

Off-white to light brown

SMILES

OC1=C(C(NCCC2=CNC3=C2C=CC=C3)=O)C=CC=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (445.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5674 mL	17.8368 mL	35.6735 mL
5 mM	0.7135 mL	3.5674 mL	7.1347 mL
10 mM	0.3567 mL	1.7837 mL	3.5674 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 96.37%

Select Batch:

Data Sheet (284 KB) SDS (393 KB)

COA (255 KB) HNMR (297 KB) RP-HPLC (250 KB) MS (70 KB)

Handling Instructions (2659 KB)

References

[1]. Gasparotto J, et al Effect of N-salicyloyltryptamine (STP), a novel tryptamine analogue, on parameters of cell viability, oxidative stress, and immunomodulation in RAW 264.7 macrophages. Cell Biol Toxicol. 2013 Jun;29(3):175-87. [Content Brief]

[2]. Araújo DA, et al. N-salicyloyltryptamine, a new anticonvulsant drug, acts on voltage-dependent Na+, Ca2+, and K+ ion channels. Br J Pharmacol. 2003 Dec;140(7):1331-9. [Content Brief]

[3]. Veras RC, et al. N-Salicyloyltryptamine, an N-Benzoyltryptamine Analogue, Induces Vasorelaxation through Activation of the NO/sGC Pathway and Reduction of Calcium Influx. Molecules. 2018 Jan 28;23(2):253. [Content Brief]

[4]. Oliveira FA, et al. Anticonvulsant properties of N-salicyloyltryptamine in mice. Pharmacol Biochem Behav. 2001 Feb;68(2):199-202. [Content Brief]

[5]. Quintans LJ Jr, et al. Bioassay-guided evaluation of antinociceptive effect of N-salicyloyltryptamine: a behavioral and electrophysiological approach. J Biomed Biotechnol. 2010;2010:230745. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.5674 mL	17.8368 mL	35.6735 mL	89.1838 mL
	5 mM	0.7135 mL	3.5674 mL	7.1347 mL	17.8368 mL
	10 mM	0.3567 mL	1.7837 mL	3.5674 mL	8.9184 mL
	15 mM	0.2378 mL	1.1891 mL	2.3782 mL	5.9456 mL
	20 mM	0.1784 mL	0.8918 mL	1.7837 mL	4.4592 mL
	25 mM	0.1427 mL	0.7135 mL	1.4269 mL	3.5674 mL
	30 mM	0.1189 mL	0.5946 mL	1.1891 mL	2.9728 mL
	40 mM	0.0892 mL	0.4459 mL	0.8918 mL	2.2296 mL
	50 mM	0.0713 mL	0.3567 mL	0.7135 mL	1.7837 mL
	60 mM	0.0595 mL	0.2973 mL	0.5946 mL	1.4864 mL
	80 mM	0.0446 mL	0.2230 mL	0.4459 mL	1.1148 mL
	100 mM	0.0357 mL	0.1784 mL	0.3567 mL	0.8918 mL